002675 东诚药业
已收盘 04-03 15:00:00
资讯
新帖
简况
4月3日东诚药业跌5.63%，银河医药混合A基金重仓该股
证券之星 · 04-03 16:15
4月3日东诚药业跌5.63%，银河医药混合A基金重仓该股
东诚药业（002675）披露回购公司股份进展情况公告，4月2日股价上涨5.46%
证券之星 · 04-02
东诚药业（002675）披露回购公司股份进展情况公告，4月2日股价上涨5.46%
3月30日东诚药业（002675）涨停分析：核药放量、管线落地、原料自主驱动
证券之星 · 03-30
3月30日东诚药业（002675）涨停分析：核药放量、管线落地、原料自主驱动
东诚药业(002675)2月28日股东户数2.71万户，较上期增加6.34%
证券之星 · 03-26
东诚药业(002675)2月28日股东户数2.71万户，较上期增加6.34%
东诚药业(002675.SZ)发布2025年度业绩，归母净利润1.96亿元，增长6.42%
智通财经 · 03-25
东诚药业(002675.SZ)发布2025年度业绩，归母净利润1.96亿元，增长6.42%
东诚药业（002675）披露225Ac-LNC1011注射液I期临床试验完成首例参与者入组，3月6日股价上涨3.59%
证券之星 · 03-06
东诚药业（002675）披露225Ac-LNC1011注射液I期临床试验完成首例参与者入组，3月6日股价上涨3.59%
东诚药业最新公告：控股子公司蓝纳成自主研发的225Ac-LNC1011注射液完成首例参与者入组
证券之星 · 03-06
东诚药业最新公告：控股子公司蓝纳成自主研发的225Ac-LNC1011注射液完成首例参与者入组
股市必读：东诚药业（002675）3月4日董秘有最新回复
证券之星 · 03-05
股市必读：东诚药业（002675）3月4日董秘有最新回复
东诚药业（002675）披露回购公司股份进展情况公告，3月2日股价下跌3.08%
证券之星 · 03-02
东诚药业（002675）披露回购公司股份进展情况公告，3月2日股价下跌3.08%
东诚药业（002675）披露为下属公司提供担保的进展公告，2月24日股价上涨1.29%
证券之星 · 02-24
东诚药业（002675）披露为下属公司提供担保的进展公告，2月24日股价上涨1.29%
东诚药业（002675）披露回购公司股份进展情况的公告，2月2日股价下跌1.96%
证券之星 · 02-02
东诚药业（002675）披露回购公司股份进展情况的公告，2月2日股价下跌1.96%
东诚药业：主营业务跨多个医药细分领域
证券之星 · 01-30
东诚药业：主营业务跨多个医药细分领域
东诚药业（002675）披露肝素钠原料药通过美国FDA检查公告，1月28日股价下跌2.38%
证券之星 · 01-28
东诚药业（002675）披露肝素钠原料药通过美国FDA检查公告，1月28日股价下跌2.38%
东诚药业（002675）披露为下属公司提供担保的进展公告，1月27日股价上涨0.14%
证券之星 · 01-27
东诚药业（002675）披露为下属公司提供担保的进展公告，1月27日股价上涨0.14%
东诚药业(002675.SZ)：氟[18F]思睿肽注射液上市申请获受理
智通财经 · 01-09
东诚药业(002675.SZ)：氟[18F]思睿肽注射液上市申请获受理
1月8日增减持汇总：东诚药业等2股增持 中微公司等11股减持（表）
新浪证券 · 01-08
1月8日增减持汇总：东诚药业等2股增持 中微公司等11股减持（表）
东诚药业最新公告：取得不超1.7亿元金融机构股票回购专项贷款承诺函
证券之星 · 01-08
东诚药业最新公告：取得不超1.7亿元金融机构股票回购专项贷款承诺函
东诚药业：1月6日回购公司股份1221096股
证券日报 · 01-07
东诚药业：1月6日回购公司股份1221096股
东诚药业最新公告：拟以1亿-2亿元回购公司股份
证券之星 · 01-04
东诚药业最新公告：拟以1亿-2亿元回购公司股份
东诚药业：氟[18F]思睿肽预计2026年上半年提交NDA
证券之星 · 2025-12-30
东诚药业：氟[18F]思睿肽预计2026年上半年提交NDA
加载更多
公司概况
公司名称：
烟台东诚药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2012-05-25
主营业务：
烟台东诚药业集团股份有限公司的主营业务是放射性核素药物、抗凝血肝素类原料药及其下游制剂的生产销售。公司的主要产品是肝素钠原料药、硫酸软骨素、制剂产品、核素药物。
发行价格：
26.00
{"stockData":{"symbol":"002675","market":"SZ","secType":"STK","nameCN":"东诚药业","latestPrice":14.58,"timestamp":1775199780000,"preClose":15.45,"halted":0,"volume":45219998,"delay":0,"changeRate":-0.0563,"floatShares":743000000,"shares":825000000,"eps":0.2516,"marketStatus":"已收盘","change":-0.87,"latestTime":"04-03 15:00:00","open":15.01,"high":15.08,"low":14.48,"amount":666000000,"amplitude":0.0388,"askPrice":14.58,"askSize":1735,"bidPrice":14.57,"bidSize":112,"shortable":0,"etf":0,"ttmEps":0.2516,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775525400000},"marketStatusCode":5,"adr":0,"adjPreClose":15.45,"symbolType":"stock","openAndCloseTimeList":[[1775179800000,1775187000000],[1775192400000,1775199600000]],"highLimit":17,"lowLimit":13.91,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":824595705,"isCdr":false,"pbRate":2.93,"roa":"--","peRate":57.949126,"roe":"4.46%","epsLYR":0.2372,"committee":-0.314442,"marketValue":12023000000,"turnoverRate":0.0608,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-08。","floatMarketCap":10839000000},"requestUrl":"/m/hq/s/002675","defaultTab":"news","newsList":[{"id":"2624183655","title":"4月3日东诚药业跌5.63%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624183655","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624183655?lang=zh_cn&edition=full","pubTime":"2026-04-03 16:15","pubTimestamp":1775204103,"startTime":"0","endTime":"0","summary":"证券之星消息，4月3日东诚药业跌5.63%，收盘报14.58元，换手率6.08%，成交量45.22万手，成交额6.66亿元。重仓东诚药业的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.29亿元，最新净值0.6285，较上一交易日下跌0.03%，近一年上涨18.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300031235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","09939","BK0239","BK1574","BK1161","BK1515","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624073195","title":"东诚药业（002675）披露回购公司股份进展情况公告，4月2日股价上涨5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624073195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624073195?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:16","pubTimestamp":1775139380,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘，东诚药业报收于15.45元，较前一交易日上涨5.46%，最新总市值为127.4亿元。该股当日开盘14.51元，最高15.48元，最低14.4元，成交额达10.34亿元，换手率为9.25%。公司于近日披露《关于回购公司股份进展情况的公告》。本次回购符合相关法规及公司回购方案的规定。公司将在回购期限内继续实施回购计划，并及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200042194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623939263","title":"3月30日东诚药业（002675）涨停分析：核药放量、管线落地、原料自主驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2623939263","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623939263?lang=zh_cn&edition=full","pubTime":"2026-03-30 15:41","pubTimestamp":1774856488,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业3月30日涨停收盘，收盘价14.48元。今日东诚药业涨停的可能因素有：核药业务成第一大收入来源；氟[18F]思睿肽完成III期临床并递交NDA，3款创新核药进入II期、1款进入III期；上游关键阿尔法同位素实现国产毫居里级量产，打破进口依赖；2025年扣非净利同比大增126.51%，经营现金流净额同比+101.9%；叠加礼来与英硅智能达成27.5亿美元AI制药合作引发创新药板块集体走强。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000015791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622752858","title":"东诚药业(002675)2月28日股东户数2.71万户，较上期增加6.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622752858","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622752858?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:14","pubTimestamp":1774516469,"startTime":"0","endTime":"0","summary":"证券之星消息，近日东诚药业披露，截至2026年2月28日公司股东户数为2.71万户，较12月31日增加1616.0户，增幅为6.34%。在化学制药行业个股中，东诚药业股东户数低于行业平均水平，截至2月28日，化学制药行业平均股东户数为3.45万户。从股价来看，2025年12月31日至2026年2月28日，东诚药业区间跌幅为3.2%，在此期间股东户数增加1616.0户，增幅为6.34%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600030781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622502075","title":"东诚药业(002675.SZ)发布2025年度业绩，归母净利润1.96亿元，增长6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622502075","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622502075?lang=zh_cn&edition=full","pubTime":"2026-03-25 20:21","pubTimestamp":1774441283,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业 发布2025年年度报告，该公司营业收入为27.41亿元，同比减少4.46%。归属于上市公司股东的净利润为1.96亿元，同比增长6.42%。基本每股收益为0.2372元。报告期内，核药业务板块销售收入11.36亿元，同比增长12.21%，其中重点产品18F-FDG实现营业收入4.98亿元，同比增长18.35%，主要原因为销量增加;云克注射液实现营业收入2.27亿元，同比下降1.55%;锝标记相关药物实现营业收入1.21亿元，同比增长21.42%。此外，拟向全体股东每10股派发现金红利0.80元(含税)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东诚药业(002675.SZ)发布2025年度业绩，归母净利润1.96亿元，增长6.42%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617763521","title":"东诚药业（002675）披露225Ac-LNC1011注射液I期临床试验完成首例参与者入组，3月6日股价上涨3.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617763521","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617763521?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:28","pubTimestamp":1772807302,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，东诚药业报收于12.69元，较前一交易日上涨3.59%，最新总市值为104.64亿元。该股当日开盘12.26元，最高12.76元，最低12.22元，成交额达1.35亿元，换手率为1.44%。近日，烟台东诚药业集团股份有限公司控股子公司烟台蓝纳成生物技术股份有限公司自主研发的225Ac-LNC1011注射液I/II期临床试验完成首例参与者入组。本次临床试验旨在评价药物在患者中的安全性、耐受性、药代动力学及初步有效性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600040346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617687498","title":"东诚药业最新公告：控股子公司蓝纳成自主研发的225Ac-LNC1011注射液完成首例参与者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687498","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617687498?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:10","pubTimestamp":1772799054,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称，公司控股子公司蓝纳成研发的225Ac-LNC1011注射液I/II期临床完成首例参与者入组，该药物为靶向PSMA的放射性体内治疗药物，拟用于治疗PSMA阳性的转移性去势抵抗性前列腺癌（mCRPC）患者。目前国内外暂无同核素产品上市。药品研发周期长，存在不确定性，敬请投资者谨慎决策。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600036273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617571975","title":"股市必读：东诚药业（002675）3月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2617571975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617571975?lang=zh_cn&edition=full","pubTime":"2026-03-05 01:02","pubTimestamp":1772643739,"startTime":"0","endTime":"0","summary":"截至2026年3月4日收盘，东诚药业报收于12.24元，下跌2.86%，换手率1.22%，成交量9.1万手，成交额1.13亿元。投资者： 董秘您好.截止2月28日公司股东人数是多少？公司股东人数在定期报告中予以披露，如确需查询非定期报告时点的股东人数，您可持个人或机构有效证件、股东账户卡、持股证明到公司办公地进行查询，或将该等有效证明文件、查询要求及联系方式发至邮箱，我们将在核实您的股东身份信息后尽快回复您，如有不明之处，可电话咨询。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500000583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616355441","title":"东诚药业（002675）披露回购公司股份进展情况公告，3月2日股价下跌3.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616355441?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:50","pubTimestamp":1772463029,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，东诚药业报收于12.89元，较前一交易日下跌3.08%，最新总市值为106.29亿元。该股当日开盘13.17元，最高13.17元，最低12.76元，成交额达1.61亿元，换手率为1.67%。近日，烟台东诚药业集团股份有限公司披露《关于回购公司股份进展情况的公告》。公告显示，公司于2025年12月31日召开董事会，审议通过以集中竞价方式回购股份的方案，拟使用自有及自筹资金回购股份，用于股权激励和/或员工持股计划。回购符合相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613138737","title":"东诚药业（002675）披露为下属公司提供担保的进展公告，2月24日股价上涨1.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613138737","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613138737?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:24","pubTimestamp":1771932245,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，东诚药业报收于13.37元，较前一交易日上涨1.29%，最新总市值为110.25亿元。近日，东诚药业披露《关于为下属公司提供担保的进展公告》。本次担保事项已经公司第六届董事会第九次会议和2024年度股东大会审议通过，属于公司2025年度对子公司及其下属公司担保额度预计范围内。截至公告日，公司实际对外担保余额为75,200万元，占公司2024年经审计净资产的16.78%，无逾期担保、诉讼等情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400039067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608185767","title":"东诚药业（002675）披露回购公司股份进展情况的公告，2月2日股价下跌1.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608185767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608185767?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:56","pubTimestamp":1770026178,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，东诚药业报收于13.5元，较前一交易日下跌1.96%，最新总市值为111.32亿元。该股当日开盘13.69元，最高13.86元，最低13.48元，成交额达1.54亿元，换手率为1.52%。近日，东诚药业发布《关于回购公司股份进展情况的公告》。公告指出，本次回购符合相关法规及公司既定方案，公司未在禁止期间回购股票，委托价格和交易时段均符合监管要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200026700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607606375","title":"东诚药业：主营业务跨多个医药细分领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2607606375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607606375?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:03","pubTimestamp":1769734989,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业(002675)01月29日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司有用于防预和治疗病毒相关药物吗？东诚药业回复：您好，公司的主要业务包括核医药业务、原料药业务板块和制剂业务板块，主营业务跨多个医药细分领域，覆盖放射性核素药物全链条产业、抗凝血肝素类原料药的生产销售及其下游制剂延伸扩展。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000008008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1515","09939","BK1574","002675","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606717941","title":"东诚药业（002675）披露肝素钠原料药通过美国FDA检查公告，1月28日股价下跌2.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606717941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606717941?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:20","pubTimestamp":1769610031,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，东诚药业报收于13.93元，较前一交易日下跌2.38%，最新总市值为114.87亿元。公司近日披露《关于肝素钠原料药通过美国FDA检查的公告》。公告显示，烟台东诚药业集团股份有限公司于2025年12月8日至12月11日接受了美国FDA的cGMP现场检查，检查范围为肝素钠原料药。此次通过检查表明公司质量体系持续符合FDA cGMP要求，有助于公司肝素钠原料药在美国及全球市场的持续拓展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800042721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606202704","title":"东诚药业（002675）披露为下属公司提供担保的进展公告，1月27日股价上涨0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606202704","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606202704?lang=zh_cn&edition=full","pubTime":"2026-01-27 17:32","pubTimestamp":1769506377,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘，东诚药业报收于14.27元，较前一交易日上涨0.14%，最新总市值为117.67亿元。公司于近日披露《关于为下属公司提供担保的进展公告》。本次担保在公司2025年度为子公司及其下属公司提供担保额度预计范围内，已经第六届董事会第九次会议和2024年度股东大会审议通过。截至公告日，公司实际对外担保余额为55,200万元，占公司2024年经审计净资产的12.32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700029743.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602378030","title":"东诚药业(002675.SZ)：氟[18F]思睿肽注射液上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2602378030","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602378030?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:07","pubTimestamp":1767960474,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业(002675.SZ)公告，公司控股子公司烟台蓝纳成生物技术股份有限公司(“蓝纳成”)收到国家药品监督管理局核准签发的关于蓝纳成在研药品氟[18F]思睿肽注射液上市许可申请的《受理通知书》。氟[18F]思睿肽注射液是一种靶向PSMA的放射性体内诊断药物，适用于下述前列腺癌患者前列腺特异性膜抗原(PSMA)阳性病灶的正电子发射断层扫描(PET)成像：(1)拟接受初始根治性治疗，怀疑存在转移灶的前列腺癌患者;(2)血清前列腺特异性抗原(PSA)水平升高，怀疑生化复发的前列腺癌患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601367364","title":"1月8日增减持汇总：东诚药业等2股增持 中微公司等11股减持（表）","url":"https://stock-news.laohu8.com/highlight/detail?id=2601367364","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601367364?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:40","pubTimestamp":1767879600,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 据统计，1月8日，盘后东诚药业、新开源披露增持情况。包括中微公司、*ST建艺（维权）、宏润建设、ST易购、华峰测控、筑博设计、泰福泵业、来伊份、佳力图、沪硅产业、豫光金铅在内的11家A股上市公司披露减持情况。\n\n\n\n新浪声明：此消息系转载自新浪合作媒体，新浪网登载此文出于传递更多信息之目的，并不意味着赞同其观点或证实其描述。文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-01-08/doc-inhfreqm6541802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1997245094.SGD","LU2289578879.USD","LU1997245177.USD","LU1997244956.HKD","BK0251","BK0239","LU2211815571.USD","002675","LU2495084118.USD","688012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601357298","title":"东诚药业最新公告：取得不超1.7亿元金融机构股票回购专项贷款承诺函","url":"https://stock-news.laohu8.com/highlight/detail?id=2601357298","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601357298?lang=zh_cn&edition=full","pubTime":"2026-01-08 17:49","pubTimestamp":1767865778,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称，公司近日取得招商银行烟台分行出具的《贷款承诺函》，承诺为公司本次回购股份专项贷款融资提供支持，贷款金额不超过人民币17,000万元（且贷款金额不得超过实际回购金额的90%），期限不超过36个月，承诺函有效期自出具之日起至2027年1月5日止。该事项不构成关联交易，不会对公司经营及业绩产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800028707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601803777","title":"东诚药业：1月6日回购公司股份1221096股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601803777","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601803777?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:33","pubTimestamp":1767789180,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月7日，东诚药业发布公告称，2026年1月6日，公司首次通过股份回购专用证券账户以集中竞价方式回购公司股份1，221，096股，占公司总股本的比例为0.1481%。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-07/doc-inhfnvir2072425.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-07/doc-inhfnvir2072425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600906044","title":"东诚药业最新公告：拟以1亿-2亿元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2600906044","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600906044?lang=zh_cn&edition=full","pubTime":"2026-01-04 16:40","pubTimestamp":1767516012,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称，公司计划以集中竞价方式回购股份，金额不低于1亿元（含），不超过2亿元（含），用于实施股权激励和/或员工持股计划。若未能在回购实施结果暨股份变动公告日后三年内转让完毕已回购股份，未转让的已回购股份将履行相关程序予以注销。回购价格不超过18.00元/股，回购期限为自董事会审议通过方案之日起12个月内。公司已召开第六届董事会第十七次会议审议通过该回购方案。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010400002057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595276383","title":"东诚药业：氟[18F]思睿肽预计2026年上半年提交NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2595276383","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595276383?lang=zh_cn&edition=full","pubTime":"2025-12-30 11:33","pubTimestamp":1767065634,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业12月29日在投资者关系平台上答复投资者关心的问题。想集中咨询公司上市前关键产品进展：1. 18F-APN-1607的杂质补充研究是否完成？99mTc-GSA的pre-NDA沟通进展如何？盼披露以明晰市场抢占节奏，感谢东诚药业回复：您好，公司在研产品正在稳步推进中，其中氟[18F]思睿肽注射液预计2026年上半年提交NDA，氟[18F]阿法肽注射液预计2027年提交NDA。公司将积极推动研发进度，争取产品尽早上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000016074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775450454727,"stockEarnings":[{"period":"1week","weight":0.1079},{"period":"1month","weight":0.1912},{"period":"3month","weight":0.0611},{"period":"6month","weight":-0.0408},{"period":"1year","weight":0.0806},{"period":"ytd","weight":0.0611}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":-0.0496},{"period":"3month","weight":-0.0224},{"period":"6month","weight":-0.0007},{"period":"1year","weight":0.161},{"period":"ytd","weight":-0.0224}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"烟台东诚药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"27096人(较上一季度增加6.34%)","perCapita":"27435股","listingDate":"2012-05-25","address":"山东省烟台市福山区经济技术开发区长白山路7号","registeredCapital":"82459万元","survey":" 烟台东诚药业集团股份有限公司的主营业务是放射性核素药物、抗凝血肝素类原料药及其下游制剂的生产销售。公司的主要产品是肝素钠原料药、硫酸软骨素、制剂产品、核素药物。","listedPrice":26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东诚药业,002675,东诚药业股票,东诚药业股票老虎,东诚药业股票老虎国际,东诚药业行情,东诚药业股票行情,东诚药业股价,东诚药业股市,东诚药业股票价格,东诚药业股票交易,东诚药业股票购买,东诚药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}